Cargando…

Numerical scoring for the BILAG-2004 index

Objective. To develop an additive numerical scoring scheme for the BILAG-2004 index. Methods. SLE patients were recruited into this multi-centre cross-sectional study. At every assessment, data were collected on disease activity and therapy. Logistic regression was used to model an increase in thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yee, Chee-Seng, Cresswell, Lynne, Farewell, Vernon, Rahman, Anisur, Teh, Lee-Suan, Griffiths, Bridget, Bruce, Ian N., Ahmad, Yasmeen, Prabu, Athiveeraramapandian, Akil, Mohammed, McHugh, Neil, D’Cruz, David, Khamashta, Munther A., Isenberg, David A., Gordon, Caroline
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919194/ https://www.ncbi.nlm.nih.gov/pubmed/20181671 http://dx.doi.org/10.1093/rheumatology/keq026

Ejemplares similares

The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally
por: Yee, Chee-Seng, et al.
Publicado: (2012)

Numerical scoring for the Classic BILAG index
por: Cresswell, Lynne, et al.
Publicado: (2009)

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity
por: Yee, Chee-Seng, et al.
Publicado: (2009)

British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
por: Yee, Chee-Seng, et al.
Publicado: (2007)

The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients
por: Yee, Chee-Seng, et al.
Publicado: (2012)

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients
por: Yee, Chee-Seng, et al.
Publicado: (2011)

The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients
por: Yee, Chee-Seng, et al.
Publicado: (2022)

Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
por: Carter, Lucy M, et al.
Publicado: (2022)

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
por: McCarthy, Eoghan M, et al.
Publicado: (2018)

Predictors of BILAG-based outcomes in patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
por: David, Trixy, et al.
Publicado: (2023)

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine
por: Reynolds, John A, et al.
Publicado: (2022)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Flares in patients with systemic lupus erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2020)

How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index
por: Ali, Sasha, et al.
Publicado: (2023)

Correction to: How can we accurately measure disease activity during pregnancy in systemic lupus erythematosus? New insights from the BILAG-2004 Pregnancy Index
Publicado: (2023)

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment
por: Cohen, Hannah, et al.
Publicado: (2017)

Antibodies to domain I of β-2-glycoprotein I and IgA antiphospholipid antibodies in patients with ‘seronegative’ antiphospholipid syndrome
por: Cousins, Laura, et al.
Publicado: (2015)

Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study
por: Mahmoud, Khaled, et al.
Publicado: (2021)

The Antiphospholipid Syndrome
por: Hughes, Graham R V, et al.
Publicado: (1994)

Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1
por: Lewis, Myles J., et al.
Publicado: (2016)

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
por: Dyball, Sarah, et al.
Publicado: (2021)

Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin
por: Manson, Jessica J, et al.
Publicado: (2014)

Dirichlet negative multinomial regression for overdispersed correlated count data
por: Farewell, Daniel M., et al.
Publicado: (2013)

Study design
por: Farewell, Vernon T., et al.
Publicado: (2016)

Equity in healthcare for coronary heart disease, Wales (UK) 2004–2010: A population-based electronic cohort study
por: King, William, et al.
Publicado: (2017)

Dengue in Singapore from 2004 to 2016: Cyclical Epidemic Patterns Dominated by Serotypes 1 and 2
por: Rajarethinam, Jayanthi, et al.
Publicado: (2018)

Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up
por: Luo, Weike, et al.
Publicado: (2022)

Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study
por: Manson, Jessica J, et al.
Publicado: (2009)

Literature review of lupus nephritis From the Arabian Gulf region
por: Al-Shujairi, Arwa, et al.
Publicado: (2022)

A multistate model for events defined by prolonged observation
por: Farewell, Vernon T., et al.
Publicado: (2011)

Likelihood estimation for a longitudinal negative binomial regression model with missing outcomes
por: Bond, Simon J, et al.
Publicado: (2009)

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
por: Cohen, Hannah, et al.
Publicado: (2016)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

The Kuwait National Primary Immunodeficiency Registry 2004–2018
por: Al-Herz, Waleed, et al.
Publicado: (2019)

The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin
por: Giles, Ian, et al.
Publicado: (2005)

Using linear increment models for the imputation of missing composite outcomes in randomized trials
por: O’Keeffe, Aidan G, et al.
Publicado: (2011)

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
por: Cohen, H, et al.
Publicado: (2015)

The versatility of multi-state models for the analysis of longitudinal data with unobservable features
por: Farewell, Vernon T., et al.
Publicado: (2012)

Partially hidden multi-state modelling of a prolonged disease state defined by a composite outcome
por: Farewell, Vernon T., et al.
Publicado: (2019)

Incidence and antibiotic prescribing for clinically diagnosed urinary tract infection in older adults in UK primary care, 2004-2014
por: Ahmed, Haroon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5an133766ers5u3sb84elkunav